Search Results

Regulated information – Inside information – UCB and Zogenix announced that the companies have entered into a definitive agreement under which UCB would acquire Zogenix, Inc., a global biopharmaceutical company commercializing and developing therapies for rare diseases.

UCB (Euronext: UCB) today announced the successful completion of the previously announced transaction to acquire Zogenix (NASDAQ: ZGNX) for US$ 26.00 per share plus a milestone-based contingent value right for a potential cash payment of US$ 2.00 per share.

Zogenix (NASDAQ: ZGNX) today announced that the compensation committee of the company’s board of directors granted inducement awards to fourteen (14) new employees.

Zogenix announced that the compensation committee of the company’s board of directors granted inducement awards to nine new non-executive employees.

Zogenix announced that the compensation committee of the company’s board of directors granted inducement awards to thirteen new non-executive employees.

Zogenix announced that the compensation committee of the company’s board of directors granted inducement awards to fourteen new employees.

UCB has announced that it is acquiring Zogenix as part of plans to expand its reach into commercializing and developing treatments for rare diseases.

Zogenix, a global biopharmaceutical company developing and rare disease therapies, provided a corporate update and announced financial results for the fourth quarter and full-year ended December 31, 2021.

Zogenix, Inc. (Nasdaq: ZGNX) today announced its intention to offer, subject to market and other conditions, $200,000,000 aggregate principal amount of convertible senior notes due 2027 (the “notes”) in a private offering to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the “Securities Act”). Zogenix also expects to grant the initial purchasers of the notes an option to purchase, for set